rs545032318
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_006073.4(TRDN):c.502G>T(p.Glu168Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000203 in 1,332,006 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_006073.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TRDN | NM_006073.4 | c.502G>T | p.Glu168Ter | stop_gained | 6/41 | ENST00000334268.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TRDN | ENST00000334268.9 | c.502G>T | p.Glu168Ter | stop_gained | 6/41 | 1 | NM_006073.4 | A2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.0000203 AC: 27AN: 1332006Hom.: 0 Cov.: 29 AF XY: 0.0000184 AC XY: 12AN XY: 652602
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Catecholaminergic polymorphic ventricular tachycardia 1 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 15, 2023 | Variant summary: TRDN c.502G>T (p.Glu168X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic within ClinVar (e.g. c.531del [p.Glu178fs], c.541G>T [p.Glu181Ter]). The variant was absent in 140800 control chromosomes (gnomAD). c.502G>T has been reported in the literature in compound heterozygous individuals affected with Cardiac Arrest and Ventricular Febrillation (Walsh_2016). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters have assessed the variant since 2014: both classifid the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 22, 2023 | This sequence change creates a premature translational stop signal (p.Glu168*) in the TRDN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TRDN are known to be pathogenic (PMID: 22422768, 25922419, 26200674, 30649896). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with TRDN-related conditions (PMID: 26768964). ClinVar contains an entry for this variant (Variation ID: 838068). For these reasons, this variant has been classified as Pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 26, 2023 | The p.E168* pathogenic mutation (also known as c.502G>T), located in coding exon 6 of the TRDN gene, results from a G to T substitution at nucleotide position 502. This changes the amino acid from a glutamic acid to a stop codon within coding exon 6. This variant has co-occurred in trans with a second TRDN pathogenic variant in siblings with sudden cardiac arrest in childhood, ventricular fibrillation, prolonged or borderline QTc interval and/or bidirectional ventricular tachycardia (Walsh MA et al. Pacing Clin Electrophysiol, 2016 May;39:497-501). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Catecholaminergic polymorphic ventricular tachycardia 5 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 16, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at